Phase 2 N=61 Study of Pharmacology of 17-OHPC in Pregnancy
Pregnancy
Primary: Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy. — 115; 136 ng/ML/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
Phase 2 N=126 Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
Esophageal Cancer · Gastroesophageal Cancer
Primary: Pathologic Complete Response Rate — 13; 26 percentage of participants
Phase 2 N=63 A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
Tumors
Primary: Progression Free Survival (PFS) in the Intent-to-Treat Population — 9.3; 8.6 months
Phase 2 N=264 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
Venous Thromboembolism · Thromboembolism · Thrombosis
Primary: Percentage of Subjects With Venous Thromboembolism Events — 3.8; 2.8; 4.1 percent of participants with VTE event
Phase 2 N=30 Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Response Rate to the Combination of Gemcitabine and Docetaxel in Patients With Platinum Sensitive and Resistant Epithelial Ovarian or Peritoneal Cancer. — 62 percentage…
Phase 2 N=38 Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation
Head Lice Infestation
Primary: Number of the Subjects With AEs. — 8 participants
Phase 2 N=90 A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Percentage of Participants With Disease Progression or Death — 61.1 percentage of participants
Phase 2 N=15 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Number of Participants With Dose-limiting Toxicity (Phase I) — 0; 0; 0; 1 participants
Phase 2 N=14 Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Area Under the Postprandial Curve (AUC) for Rate of Appearance (Ra) of Exogenous Glucose — 101.97; 93.89; 63.84; 97.76 (umol/kg FFM/min)*hr
Phase 2 N=602 Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
Depressive Disorder, Major
Primary: Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST) — 4.60; 4.06; 2.85 Correct symbols — p=0.019
Phase 2 N=10 Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study
Muscle Cramps · Cirrhosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache) — 3 participants
Phase 2 N=231 Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Polio Immunity
Primary: Post Booster Polio Neutralizing Antibody Titers — 1715; 976; 1249; 1328 antibody titers
Phase 2 N=30 Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
Hepatitis C, Chronic
Primary: Incidence Of Sustained Virologic Response 4 Weeks (SVR4) After The Completion Of Treatment — 50; 70; 0 Percentage of participants with SVR4
Phase 2 N=41 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate (CR + PR) — 7.5 percentage of participants